Evidence map›Paper›PMID 20808834›Full record

ArticlePloS one2010

Mitochondrial DNA variant discovery and evaluation in human Cardiomyopathies through next-generation sequencing.

Michael V Zaragoza, Joseph Fass, Marta Diegoli, Dawei Lin, Eloisa Arbustini

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Mitochondrial tRNALife (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michael V ZaragozaGenetics & Metabolism Division, Pediatrics Department and Center for Mitochondrial and Molecular Medicine and Genetics, University of California Irvine, Irvine, California, United States of America. mzaragoz@uci.edu
Joseph Fass
Marta Diegoli
Dawei Lin
Eloisa Arbustini
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of California, Davis · USUniversity of California, Irvine · US

Funding

Mitochondrial Dysfunction & Noncompaction CardiomyopathyK08HL081222 · NHLBI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZARAGOZA, MICHAEL V · 2006 to 2010
$637k
NHLBI NIH HHS K08 HL081222
6 · The paper itself

Abstract

Mutations in mitochondrial DNA (mtDNA) may cause maternally-inherited cardiomyopathy and heart failure. In homoplasmy all mtDNA copies contain the mutation. In heteroplasmy there is a mixture of normal and mutant copies of mtDNA. The clinical phenotype of an affected individual depends on the type of genetic defect and the ratios of mutant and normal mtDNA in affected tissues. We aimed at determining the sensitivity of next-generation sequencing compared to Sanger sequencing for mutation detection in patients with mitochondrial cardiomyopathy. We studied 18 patients with mitochondrial cardiomyopathy and two with suspected mitochondrial disease. We "shotgun" sequenced PCR-amplified mtDNA and multiplexed using a single run on Roche's 454 Genome Sequencer. By mapping to the reference sequence, we obtained 1,300x average coverage per case and identified high-confidence variants. By comparing these to >400 mtDNA substitution variants detected by Sanger, we found 98% concordance in variant detection. Simulation studies showed that >95% of the homoplasmic variants were detected at a minimum sequence coverage of 20x while heteroplasmic variants required >200x coverage. Several Sanger "misses" were detected by 454 sequencing. These included the novel heteroplasmic 7501T>C in tRNA serine 1 in a patient with sudden cardiac death. These results support a potential role of next-generation sequencing in the discovery of novel mtDNA variants with heteroplasmy below the level reliably detected with Sanger sequencing. We hope that this will assist in the identification of mtDNA mutations and key genetic determinants for cardiomyopathy and mitochondrial disease.

Indexed as

Genetic VariationBase SequenceCardiomyopathiesComputational BiologyDNA, MitochondrialFemaleHumansMaleMitochondrial DiseasesMutationSequence Analysis, DNADNA, Mitochondrial

Identifiers

PMID20808834
PMCPMC2924892
OpenAlexW2007018668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.